Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Reviva Pharmaceuticals Holdings (RVPH)
NASDAQ:RVPH
RESEARCH TOOLSreports
Holding RVPH?
Track your performance easily
RVPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.60 - $6.30
Previous Close$1
Volume4.00M
Average Volume (3M)503.10K
Market Cap
$33.44M
Enterprise Value$27.47M
Total Cash (Recent Filing)$6.18M
Total Debt (Recent Filing)$207.50K
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Mar 24, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding33,090,000
10 Day Avg. Volume829,960
30 Day Avg. Volume503,096
Standard Deviation0.48
R-Squared0.00
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-7.33
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.36
Forecast
1Y Price Target
$15.00Price Target Upside1036.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Reviva Pharmaceuticals Holdings News
PremiumCompany Announcements
Reviva Pharmaceuticals Progresses with Brilaroxazine Study Update
PremiumCompany Announcements
Reviva Pharmaceuticals Launches Multi-Million Share OfferingBulls Say, Bears Say
Bulls Say
Intellectual PropertyNew U.S. brilaroxazine use patent granted.
Market Expansion PotentialSuccessful development and commercialization in non-neuropsychiatric indications—such as pulmonary hypertension, pulmonary arterial hypertension, IPF, and psoriasis, among others—would all constitute potential drivers of future upside to forecasts.
Regulatory MilestonesFDA alignment has been secured for the study design of the upcoming P3 'RECOVER-2' study.
Bears Say
Financial PerformanceThe company reported a net loss of $7.9 million and has only $6.2 million in cash, raising concerns about its financial stability.
Funding And Capital NeedsThe initiation of the company's second Phase 3 study has been postponed, likely due to funding constraints, which may impact future growth prospects.
Operational RisksSignificant risks include the potential failure to complete the pivotal development of the lead program in schizophrenia and the inability to establish a commercial partnership for global marketing.
---
Ownership Overview
6.28%
Insiders
3.71% Mutual Funds
0.18% Other Institutional Investors
86.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVPH FAQ
What was Reviva Pharmaceuticals Holdings’s price range in the past 12 months?
Reviva Pharmaceuticals Holdings lowest stock price was $0.60 and its highest was $6.30 in the past 12 months.
What is Reviva Pharmaceuticals Holdings’s market cap?
Currently, no data Available
When is Reviva Pharmaceuticals Holdings’s upcoming earnings report date?
Reviva Pharmaceuticals Holdings’s upcoming earnings report date is Mar 24, 2025 which is in 131 days.
How were Reviva Pharmaceuticals Holdings’s earnings last quarter?
Currently, no data Available
Is Reviva Pharmaceuticals Holdings overvalued?
According to Wall Street analysts Reviva Pharmaceuticals Holdings’s price is currently Undervalued.
Does Reviva Pharmaceuticals Holdings pay dividends?
Reviva Pharmaceuticals Holdings does not currently pay dividends.
What is Reviva Pharmaceuticals Holdings’s EPS estimate?
Reviva Pharmaceuticals Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Reviva Pharmaceuticals Holdings have?
Reviva Pharmaceuticals Holdings has 33,441,200 shares outstanding.
What happened to Reviva Pharmaceuticals Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Reviva Pharmaceuticals Holdings?
Among the largest hedge funds holding Reviva Pharmaceuticals Holdings’s share is Woodline Partners LP. It holds Reviva Pharmaceuticals Holdings’s shares valued at 2M.
---
Reviva Pharmaceuticals Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (1036.36% Upside)
$15.00 (1036.36% Upside)
Blogger Sentiment
Bullish
RVPH Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 537.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-32.00%
Trailing 12-Months
Company Description
Reviva Pharmaceuticals Holdings
Tenzing Acquisition Corp. is a blank check company, which engages in the acquisition of similar business combination with one or more businesses and entities. It focuses on the merger, capital stock exchange, asset acquisition, stock purchase, reorganization, recapitalization, and exchangeable share transaction. The company was founded on March 20, 2018 and is headquartered in New York, NY.
---
RVPH Stock 12 Month Forecast
Average Price Target
$15.00
▲(1036.36% Upside)
Technical Analysis
Best Analysts Covering RVPH
1 Year
1 Year Success Rate
1/14 ratings generated profit
1 Year Average Return
-56.76%
reiterated a buy rating 3 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 7.14% of your transactions generating a profit, with an average return of -56.76% per trade.
---